CRISPR Gene-Editing Therapy Ends Painful Crises in Sickle Cell Trial

Sickle cell disease causes red blood cells to deform into rigid crescents that clog blood vessels, triggering episodes of excruciating pain called vaso-occlusive crises and, over time, organ damage. For most patients, options have been limited to managing symptoms or undergoing risky bone-marrow transplants. A study published in the New England Journal of Medicine, reported in 2026, points toward something closer to a functional cure.

The therapy, renizgamglogene autogedtemcel — reni-cel — is a one-time treatment built on CRISPR-Cas12a gene editing. Doctors collect a patient's own blood stem cells and use the gene-editing tool to switch back on production of fetal hemoglobin, a form of the oxygen-carrying protein that the body normally makes only before birth. Reactivating it dilutes the faulty adult hemoglobin and keeps red cells from sickling. The corrected cells are then returned to the patient.

“For most patients, options have been limited to managing symptoms or undergoing risky bone-marrow transplants.”

The results from the phase 1–2 RUBY trial were striking. Among the patients treated and followed, 27 of 28 had no vaso-occlusive crises after receiving reni-cel. Total hemoglobin rose to normal levels — averaging about 13.8 grams per deciliter from a baseline near 9.8 — and fetal hemoglobin climbed to roughly 48% and stayed stable over time. For people who had lived with recurrent, hospitalizing pain, the elimination of crises is a life-changing shift.

As with any new gene therapy, caution is warranted. The treatment requires intensive chemotherapy conditioning before the edited cells are infused, follow-up so far is measured in months to a few years, and longer monitoring is needed to confirm the benefit endures and to fully characterize safety. The complex, individualized manufacturing also raises real questions about cost and access. Still, for a disease that has long lacked good options, a one-time therapy that stops the crises and restores healthy blood is a profound and hopeful advance.